Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18418178 | 0.83 | SMN1; SMN2 (0.52) | MGLLNAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL20025275 | 0.81 | USP2 (0.50) | MGLLNAMPTUSP2SMN1; SMN2RECQL | |
| SCHEMBL20555903 | 0.80 | USP2 (0.47) | MGLLNAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL17328229 | 0.79 | MGLL (0.70) | MGLLNAMPTGPR119 | |
| SCHEMBL24803194 | 0.78 | USP2 (0.54) | MGLLNAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL12626975 | 0.78 | USP2 (0.44) | USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL2960741 | 0.78 | USP2 (0.51) | MGLLNAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL18053621 | 0.77 | USP2 (0.59) | MGLLUSP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL18418201 | 0.77 | MGLL (0.72) | MGLLNAMPT | |
| SCHEMBL20058341 | 0.77 | MGLL (0.44) | MGLLNAMPTUSP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065971-B2 | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-04 | — | — | US | disclosed |
| EP-3149005-B1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE LABOR DR (ES) | 2018-04-18 | — | — | EP | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| WO-2015185208-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065971-B2 | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, SIGMAR1, OPRM1 | MGLL 3651/4885NAMPT 3307/4885USP2 2074/4885 |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | MGLL 3651/4885NAMPT 3307/4885USP2 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.